• 周金培

    药物化学系 教授
    领域:新药物分子研究
    联系电话:
    电子邮箱:zhjp@cpu.edu.cn
    办公室:江宁校区学院实验楼502室
    实验室:江宁校区学院实验楼530D
  • 1、教育经历
    (1) 1996/09-1999/07,学院,澳门十大老牌信誉平台排行榜,博士
    (2) 1986/09-1989/07,学院,澳门十大老牌信誉平台排行榜,硕士
    (3) 1982/09-1986/07,南京澳门十大老牌信誉平台排行榜,学士
    2、工作经历
    (1) 1999/09 至今, 学院,澳门十大老牌信誉平台排行榜, 教授
    (2) 1989/08-1996/08,江苏省农药研究所,工程师
    (3) 2005/04-2006/04,日本国岐阜药科大学,澳门十大老牌信誉平台排行榜 访问学者
    (1) 新型靶向药物合成研究
    (2) 新型小分子免疫调节剂药物研究
    (1)国家重点实验室重点任务, LG202103-02-08,以Sting为靶点的候选新药及其机制研究 , 2021/11-2022/10 , 250万,主持。
    (2)国家高技术研究发展计划(863计划),2003AA2Z3530、兼有心血管作用的降糖药物设计合成及活性研究,2003/01-2006/12,20万,结题,主持。
    (3)南京市回国人员基金,2007,具有抗肿瘤活性的1,4取代哌啶类化合物的设计、合成与生物活性研究,2007/01-2008/12、1.5万,结题,主持。
    (4)国家重大专项,2013ZX09102013,新型降血糖药物G004的临床前研究,2013.1-2015.12、288万,结题,子课题负责人。
    (5)江苏省产学研联合创新基金前瞻性联合研究项目,BY2011158,2011/01-2013/12、50万,结题,参与。
    (6)国家自然科学基金项目,30973638、G004抗TXA2受体介导的心血管并发症机制及受体作用模式、2009/01-2012/12、34万,结题,参与。
    (7)国家重大专项,2009ZX09103-094、新型降血糖药物G004的研究开发、2009/01-2012/12,141万,结题,,课题副组长。
    1.Yifei Yang, Pan Chen, Leilei Zhao, Bing Zhang, Changliang Xu*, Huibin Zhang*, Jinpei Zhou*. Design, synthesis and biological evaluation of imidazolopyridone derivatives as novel BRD4 inhibitors. Bioorganic & Medicinal Chemistry, 29(2021)115857 IF3.641
    2.Xinrui Yuan, Hong Bu, Jinpei Zhou*, Chao-Yie Yang,* and Huibin Zhang*. Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application, J Med Chem, 63 (2020): 11368-11396. IF6.205
    3.Jian Zhang, Pan Chen, Peiyu Zhu, Peiyuan Zheng, Tao Wang, Lixun Wang, Changliang Xu*, Jinpei Zhou*, Huibin Zhang*. Development of small-molecule BRD4 degraders based on pyrrolopyridone derivative, Bioorg. Chem, 99 (2020): 103817. IF4.831
    4.Yifei Yang, Lincheng Fang, Pan Chen, Huibin Zhang,* and Jinpei Zhou*. Identification of 3,5-Dimethylisoxazole Derivatives as BRD4 Inhibitors for the Treatment of Colorectal Cancer, ACS Med Chem Lett, 11 (2020): 2174-2181. IF3.975,
    5.Yifei Yang‡, Zhenwei Wu‡, Pan Chen, Peiyuan Zheng, Huibin Zhang*, Jinpei Zhou**. Proteolysis-targeting chimeras mediate the degradation of bromodomain and extra-terminal domain proteins, Future Med Chem, 12 (2020): 1669-1683. IF3.607
    6.Qiangqiang Wei, Liankuo Mei, Pan Chen, Xinrui Yuan, Huibin Zhang*, Jinpei Zhou*. Design, synthesis and biological evaluation of novel chroman derivatives as non-selective acetyl-CoA carboxylase inhibitors, Bioorg Chem, 101 (2020): 103943. IF4.831
    7.Shi Cai, Xiaojun Yang, Pan Chen , Xueting Liu, Jinpei Zhou*, Huibin Zhang*. Design, synthesis and biological evaluation of bicyclic carboxylic acid derivatives as IDO1 inhibitors, Bioorg. Chem. 2020 Jan;94:103356. IF4.831
    8.Xialin Zhu, Yun Chen, Xu Xu, Xiaoju Xu, Yin Lu, Xi Huang, Jinpei Zhou* , Lihong Hu, Jiaying Wang*, Xu Shen*. SP6616 as a Kv2.1 inhibitor efficiently ameliorates peripheral neuropathy in diabetic mice. EbioMedicine. 2020 Nov;61:103061. IF5.736
    9.Xinrui Yuan, Hanshu Wu, Hong Bu, Jinpei Zhou*, Huibin Zhang*.Targeting the immunity protein kinases for immuno-oncology. European Journal of Medicinal Chemistry. 2019,163:413-427 IF 4.833
    10.Yifei Yang, Pan Chen, Leilei Zhao, Fangqing Zhang, Bing Zhang, Changliang Xu*, Huibin Zhang*, Jinpei Zhou*. Exploiting the 7-methylimidazo[1,5-a]pyrazin-8(7H)-one scaffold for the development of novel chemical inhibitors for Bromodomain and Extraterminal Domain (BET) family. Bioorg. Chem. 2019,90:103044 IF3.926
    Baidu
    sogou